New appointment at NovaBay Pharmaceuticals
This article was originally published in Scrip
Executive Summary
NovaBay Pharmaceuticals, a US clinical-stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a range of bacterial, viral and fungal infections, has appointed Dr Mark Anderson to the new position of chief scientific officer. He has previously held senior positions at Myriad Genetics, Elitra Pharmaceuticals, Pfizer-Agouron and Ligand-Glycomed.